Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?

Hims & Hers Health (HIMS) has seen its shares outperform, gaining +8.5% over the past month against the S&P 500's +2.7%. Despite robust projected revenue growth, with current fiscal year sales estimated at $2.35 billion (+59.4% YoY), the company has experienced significant negative revisions to its earnings estimates, notably a -39.6% change for the current quarter's EPS over the last 30 days. HIMS also reported a -1.51% revenue and -5.56% EPS surprise last quarter, and its valuation is assessed at a premium to peers (Zacks Value Style Score 'D'), leading Zacks to assign a 'Hold' (Rank #3) rating, indicating expected near-term performance in line with the broader market.

Analysis

Hims & Hers Health, Inc. (HIMS) presents a conflicting profile of robust top-line growth set against deteriorating earnings expectations and a premium valuation. The company's stock has significantly outperformed the market recently, returning +8.5% over the past month versus the S&P 500's +2.7% gain. This is supported by strong revenue forecasts, with consensus estimates pointing to +45.1% year-over-year growth for the current quarter and +59.4% for the full fiscal year. However, this growth narrative is challenged by significant negative revisions to earnings estimates by sell-side analysts. Over the last 30 days, the consensus EPS estimate for the current quarter has been revised downward by a substantial -39.6%, with full-year and next-year estimates also cut by -12.2% and -14.1% respectively. This pessimism is contextualized by the company's most recent earnings report, where it missed both revenue and EPS consensus estimates by -1.51% and -5.56%. Furthermore, its valuation appears stretched, as indicated by a Zacks Value Style Score of 'D', suggesting it trades at a premium to its peers. The resulting Zacks Rank of #3 (Hold) encapsulates this mixed outlook, suggesting the stock may perform in line with the broader market in the near term.

Key Decisions for Investors

• Investors should weigh the company's impressive revenue growth trajectory, with a projected +59.4% increase for the current fiscal year, against the significant recent downward revisions in earnings estimates, which signal potential pressure on profitability.
• Given the recent miss on both revenue and EPS and a history of surpassing EPS estimates only once in the last four quarters, it is prudent to monitor the next earnings release for evidence of improved execution before increasing exposure.
• The stock's premium valuation, reflected by a 'D' grade for value, suggests caution, as the market may have already priced in the high growth expectations, leaving little room for error or further negative earnings revisions.